Home / Directory
Product directory
Every product we can source, listed A to Z with its active substance and manufacturer. Open a product to enquire.
| Product | Active substance | Target | Area | Manufacturer | Type | |
|---|---|---|---|---|---|---|
| Avastin | Bevacizumab | VEGF-A | Oncology | Roche | Originator | Enquire |
| Cotellic | Cobimetinib | MEK | Oncology | Roche | Originator | Enquire |
| Darzalex | Daratumumab | CD38 | Oncology | Janssen | Originator | Enquire |
| Dupixent | Dupilumab | IL-4 receptor alpha | Immunology | Sanofi | Originator | Enquire |
| Enhertu | Trastuzumab deruxtecan | HER2 (antibody-drug conjugate) | Oncology | Daiichi Sankyo | Originator | Enquire |
| Erbitux | Cetuximab | EGFR | Oncology | Merck | Originator | Enquire |
| Eylea | Aflibercept | VEGF | Ophthalmology | Bayer | Originator | Enquire |
| Gazyvaro | Obinutuzumab | CD20 | Oncology | Roche | Originator | Enquire |
| Hepcludex | Bulevirtide | Hepatitis delta virus entry (NTCP) | Hepatology | — | Originator | Enquire |
| Herceptin | Trastuzumab | HER2 | Oncology | Roche | Originator | Enquire |
| Jaypirca | Pirtobrutinib | BTK | Oncology | — | Originator | Enquire |
| Kadcyla | Trastuzumab emtansine | HER2 (antibody-drug conjugate) | Oncology | Roche | Originator | Enquire |
| Keytruda | Pembrolizumab | PD-1 | Oncology | MSD | Originator | Enquire |
| Kisqali | Ribociclib | CDK4 and CDK6 | Oncology | Novartis | Originator | Enquire |
| Lenvima | Lenvatinib | VEGFR and other kinases | Oncology | Eisai | Originator | Enquire |
| MabThera | Rituximab | CD20 | Oncology | Roche | Originator | Enquire |
| Nemluvio | Nemolizumab | IL-31 receptor | Dermatology | Galderma | Originator | Enquire |
| Ontruzant | Trastuzumab | HER2 | Oncology | Samsung Bioepis | Biosimilar | Enquire |
| Onureg | Azacitidine | DNA hypomethylation | Oncology | BMS | Originator | Enquire |
| Opdivo | Nivolumab | PD-1 | Oncology | BMS | Originator | Enquire |
| Opdualag | Nivolumab, relatlimab | PD-1 and LAG-3 | Oncology | BMS | Originator | Enquire |
| Perjeta | Pertuzumab | HER2 | Oncology | Roche | Originator | Enquire |
| Phesgo | Trastuzumab, pertuzumab | HER2 | Oncology | — | Originator | Enquire |
| Polivy | Polatuzumab vedotin | CD79b (antibody-drug conjugate) | Oncology | Roche | Originator | Enquire |
| Remodulin | Treprostinil | Prostacyclin pathway | Cardiovascular | — | Originator | Enquire |
| Rybelsus | Semaglutide | GLP-1 receptor | Metabolic | Novo Nordisk | Originator | Enquire |
| Spinraza | Nusinersen | SMN2 splicing | Neurology | Biogen | Originator | Enquire |
| Tagrisso | Osimertinib | EGFR kinase | Oncology | AstraZeneca | Originator | Enquire |
| Takhzyro | Lanadelumab | Plasma kallikrein | Immunology | Takeda | Originator | Enquire |
| Tecentriq | Atezolizumab | PD-L1 | Oncology | Roche | Originator | Enquire |
| Truxima | Rituximab | CD20 | Oncology | Celltrion | Biosimilar | Enquire |
| Vabysmo | Faricimab | Angiopoietin-2 and VEGF-A | Ophthalmology | Roche | Originator | Enquire |
| Vegzelma | Bevacizumab | VEGF-A | Oncology | Celltrion | Biosimilar | Enquire |
| Verzenios | Abemaciclib | CDK4 and CDK6 | Oncology | Eli Lilly | Originator | Enquire |
| Xalkori | Crizotinib | ALK and ROS1 kinases | Oncology | Pfizer | Originator | Enquire |
| Yervoy | Ipilimumab | CTLA-4 | Oncology | BMS | Originator | Enquire |
| Zejula | Niraparib | PARP | Oncology | GSK | Originator | Enquire |
No products match your search.